chartexchange

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc. | Oct 28, 2026 4:15 PM EDT

CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that it awarded inducement grants on October 26, 2026, to its Executive Vice President and Chief Medical Officer, Jing Marantz, M.D., Ph.D., as a material inducement to employment.

Read original article